Drug General Information |
Drug ID |
D0R2JS
|
Former ID |
DIB016627
|
Drug Name |
Droloxifene
|
Synonyms |
E-droloxifene; FK-435; K-060; K-060E; RP-60850; K-21.060E; 3-hydroxytamoxifen
|
Drug Type |
Small molecular drug
|
Indication |
Breast cancer [ICD9: 174, 175; ICD10:C50]
|
Discontinued in Phase 2 |
[1]
|
Company |
Klinge Pharma GmbH
|
Structure |
|
Download
2D MOL
3D MOL
|
Formula |
C26H29NO2
|
Canonical SMILES |
C(=C(\c1ccccc1)/CC)(/c1cc(O)ccc1)\c1ccc(cc1)OCCN(C)C
|
CAS Number |
CAS 82413-20-5
|
PubChem Compound ID |
|
Target and Pathway |
Target(s) |
Estrogen receptor |
Target Info |
Modulator |
[2]
|
KEGG Pathway
|
Estrogen signaling pathway
|
Prolactin signaling pathway
|
Thyroid hormone signaling pathway
|
Endocrine and other factor-regulated calcium reabsorption
|
Proteoglycans in cancer
|
NetPath Pathway
|
FSH Signaling Pathway
|
EGFR1 Signaling Pathway
|
RANKL Signaling Pathway
|
Pathway Interaction Database
|
Regulation of nuclear SMAD2/3 signaling
|
Signaling events mediated by HDAC Class II
|
Plasma membrane estrogen receptor signaling
|
LKB1 signaling events
|
Regulation of Telomerase
|
ATF-2 transcription factor network
|
AP-1 transcription factor network
|
FOXM1 transcription factor network
|
Validated nuclear estrogen receptor alpha network
|
Signaling mediated by p38-alpha and p38-beta
|
FOXA1 transcription factor network
|
Reactome
|
Nuclear signaling by ERBB4
|
Nuclear Receptor transcription pathway
|
WikiPathways
|
Estrogen signaling pathway
|
Nuclear Receptors Meta-Pathway
|
Estrogen Receptor Pathway
|
Signaling by ERBB4
|
JAK/STAT
|
Integrated Pancreatic Cancer Pathway
|
Leptin signaling pathway
|
miR-targeted genes in muscle cell - TarBase
|
Integrated Breast Cancer Pathway
|
Nuclear Receptors
|
References |
REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000847) |
---|
REF 2 | Droloxifene, a new antiestrogen: its role in metastatic breast cancer. Breast Cancer Res Treat. 1994;31(1):83-94. |